Stocks · News reference
JP Morgan analyst Jessica Fye reinstates Immunocore Holdings (NASDAQ:IMCR) with a Overweight and announces $50 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunocore Holdings plc announced that management will participate in multiple investor conferences in September 2026, including presentations at Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The company's lead product KIMMTRAK generated $115.9 million in Q2 2026 revenues, representing 18% year-over-year growth.
Immunocore Hldgs (NASDAQ:IMCR) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.02 by 200 percent. This is a 90 percent increase over losses of $(0.20) per share from the
Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and raises the price target from $34 to $35.